Building on over 45 years of experience with the extraction, purification and synthesis of high value intermediates and active pharmaceutical ingredients, BioVectra’s drug development activities focus on new chemical entities and generic products with complex active ingredients and challenging formulations.
Our team engages in product development in partnership with major pharmaceutical companies. Product selection capitalizes on our experience, expertise and capabilities, with specific focus on:
Over the last 10 years, BioVectra has made significant investments in expanding our services in the field of microbial metabolite fermentation. BioVectra has hands on experience at producing small molecules, proteins, and enzymes using a variety of microbial and fungal fermentation techniques. Projects have included: commercial scale production of potent compounds and antimicrobial agents from native or mutant strains, proteins from recombinant E. Coli fermentations and enzymes from filamentous bacteria or natural plant sources.
BioVectra’s fermentation labs are equipped with advanced instruments such as: parallel bioreactors for upstream process optimization, AKTA purifiers, and UF systems for protein purifications. Combined with our downstream purification capabilities in complex chemistry, BioVectra has the experience and capacity to prepare high purity, cGMP active pharmaceutical ingredients from microbial fermentation processes to support drug development projects.
Chemistry is the foundation on which BioVectra was built and with more than 45 years of experience in the chemical and pharmaceutical manufacturing industry, BioVectra has the knowledge and expertise to prepare high purity, cGMP active pharmaceutical ingredients to support drug development projects.
BioVectra’s labs are equipped with state of the art equipment and tools that have been used to support over 100 chemical API projects in various stages of clinical development. BioVectra also possesses significant experience at working with potent compounds, natural products (isolation, semi-synthesis) in addition to downstream purification of fermented metabolites.
BioVectra’s drug development activities focus on new entity and generic products with challenging active ingredients and formulations with a particular interest in complex intravenous injectable and intramuscular sustained-release formulations. BioVectra has expertise in the use of lipid and polymer-based nanoparticulate formulations for solubilization, controlled release and targeting of drugs.
BioVectra’s labs are equipped with state-of-the-art equipment for physical and chemical characterization of APIs, excipients, nanoparticle preparation, and cGMP analytical testing. Specialized equipment includes microfluidizers, thermal analysis, and physicochemical characterization tools such as particle size, surface charge and surface area analyzers.
Formulation Capabilities include:
- Nanoparticulate formulations (Lipid and Polymer based nanoparticles)
- Depot formulations (PLGA based drug delivery systems)
- Controlled release (IV and IM injectable formulations)
- High potency API formulations (Taxanes)
BioVectra’s development and manufacturing expertise is extensive and includes:
Antibody drug conjugates
MPEG chemistry and conjugation
Many other product classes and formulation methods
We welcome inquiries for drug development partnership opportunities involving new chemical entities and generic pharmaceuticals.
Please contact us to learn more about our partnering opportunities.